GSK (GSK) Stock Price, News & Analysis

Company Overview

GSK plc, formerly GlaxoSmithKline, is a global biopharmaceutical company headquartered in Brentford, England. The company focuses on researching, developing and commercializing medicines and vaccines designed to prevent and treat infectious diseases, respiratory conditions, immune-related disorders and certain cancers.

Its vaccine portfolio includes products such as Shingrix for shingles, Arexvy for respiratory syncytial virus (RSV) in older adults, and vaccines targeting meningitis, influenza and other infectious diseases. GSK also offers specialty and general medicines, including treatments for respiratory diseases, HIV and oncology. The company works with ViiV Healthcare, a specialist HIV business in which GSK is a major shareholder.

GSK serves patients and healthcare providers in markets around the world through commercial operations, research facilities and manufacturing sites across multiple regions. The company was formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham and completed the separation of its consumer healthcare business, now Haleon, in 2022. Emma Walmsley has served as GSK’s chief executive officer since 2017.

Key Stats

• Today's Range: $50.29 to $50.92
• 50-Day Range: $46.24 to $52.92
• 52-Week Range: $42.85 to $61.69
• Volume: 1.78 million shs
• Average Volume: 4.49 million shs
• Market Capitalization: $102.40 billion
• P/E Ratio: 15.83
• Dividend Yield: 3.50%
• Price Target: $55.33
• Consensus Rating: Hold

GSK Stock Analysis - MarketRank™

GSK scored higher than 68% of companies evaluated by MarketBeat, and ranked 265th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.7 / 5
• Analyst Rating: Hold

Consensus Rating

GSK has received a consensus rating of Hold. The company's average rating score is 2.05, and is based on no strong buy ratings, 4 buy ratings, 12 hold ratings, and 3 sell ratings.

Upside/Downside

The consensus price target for GSK is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

GSK has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 4.60%

Earnings Growth

Earnings for GSK are expected to grow by 4.60% in the coming year, from $4.78 to $5.00 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GSK is 15.90, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 35.81.

Price to Earnings Ratio vs. Sector

The P/E ratio of GSK is 15.90, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 205.88.

Price to Earnings Growth Ratio

GSK has a PEG Ratio of 2.25. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

GSK has a P/B Ratio of 4.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.81% of the float of GSK has been sold short.

Short Interest Ratio / Days to Cover

GSK has a short interest ratio ("days to cover") of 4.14.

Change versus previous month

Short interest in GSK has recently increased by 0.99%, indicating that investor sentiment is decreasing.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Leadership

GSK is a leading dividend payer. It pays a dividend yield of 3.54%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

GSK does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of GSK is 55.31%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, GSK will have a dividend payout ratio of 35.40% next year. This indicates that GSK will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.41

News Sentiment

GSK has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 23 news articles for GSK this week, compared to 7 articles on an average week.

Search Interest

Only 20 people have searched for GSK on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.

MarketBeat Follows

20 people have added GSK to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GSK insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.00% of the stock of GSK is held by insiders.

Percentage Held by Institutions

15.74% of the stock of GSK is held by institutions.

Company Calendar

• Last Earnings: 7/28/2026
• Record date for 10/8 Dividend: 8/14/2026
• Ex-Dividend for 10/8 Dividend: 8/14/2026
• Dividend Payable: 10/08/2026
• Today: 10/23/2026
• ESMO 2026 Investor Briefing: 10/27/2026
• Next Earnings (Estimated): 10/28/2026
• 3rd Annual Guggenheim Healthcare Innovation Conference: 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:GSK
• CIK: 1131399
• Web: www.gsk.com
• Phone: 442080475000
• Fax: 44-20-8047-7807
• Employees: 66,841
• Year Founded: 2000

Price Target and Rating

• Average Price Target for GSK: $55.33
• High Price Target: $70.00
• Low Price Target: $43.00
• Potential Upside/Downside: +9.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.05
• Research Coverage: 19 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.20
• Trailing P/E Ratio: 15.81
• Forward P/E Ratio: 10.58
• P/E Growth: 2.25
• Net Income: $7.54 billion
• Net Margins: 14.56%
• Pretax Margin: 17.84%
• Return on Equity: 43.23%
• Return on Assets: 11.60%

Debt

• Debt-to-Equity Ratio: 0.81
• Current Ratio: 0.82
• Quick Ratio: 0.52

Sales & Book Value

• Annual Sales: $43.07 billion
• Price / Sales: 2.38
• Cash Flow: $6.07 per share
• Price / Cash Flow: 8.33
• Book Value: $10.32 per share
• Price / Book: 4.90

Miscellaneous

• Outstanding Shares: 2,022,710,000
• Free Float: 1,820,435,000
• Market Cap: $102.34 billion
• Optionable: Optionable
• Beta: 0.33